These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 15759282)
1. Glucagon-like peptide 1(GLP-1) in biology and pathology. Meier JJ; Nauck MA Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282 [TBL] [Abstract][Full Text] [Related]
2. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. Creutzfeldt W Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578 [TBL] [Abstract][Full Text] [Related]
3. The potential role of glucagon-like peptide 1 in diabetes. Meier JJ; Nauck MA Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281 [TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. D'Alessio DA; Vahl TP Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755 [TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Nauck MA Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Nauck M Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470 [TBL] [Abstract][Full Text] [Related]
7. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2]. Diamant M; Bunck MC; Heine RJ Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988 [TBL] [Abstract][Full Text] [Related]
8. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Dupre J Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434 [TBL] [Abstract][Full Text] [Related]
9. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Baggio LL; Drucker DJ Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774 [TBL] [Abstract][Full Text] [Related]
10. The physiological role of GLP-1 in human: incretin, ileal brake or more? Schirra J; Göke B Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430 [TBL] [Abstract][Full Text] [Related]
11. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Patriti A; Facchiano E; Sanna A; Gullà N; Donini A Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993 [TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptide-1--a new hormone and a new drug]. Holst JJ Ugeskr Laeger; 1998 Apr; 160(16):2371-7. PubMed ID: 9571809 [TBL] [Abstract][Full Text] [Related]
13. Extrapancreatic effects of GIP and GLP-1. Vella A; Rizza RA Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. List JF; Habener JF Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Nauck MA; Meier JJ Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433 [TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapy and type 2 diabetes. Hare KJ; Knop FK Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]